Source comparison
PT-141 vs Vyleesi — Mechanism, Efficacy & Access
A 2019 FDA approval press release stated that Vyleesi (bremelanotide) was the first melanocortin receptor agonist approved for acquired, generalized HSDD in premenopausal women. Yet the compound itself had been studied under the name PT-141 for over a decade b
This comparison does not assign a generated winner or score.
- A 2019 FDA approval press release stated that Vyleesi (bremelanotide) was the first melanocortin receptor agonist approved for acquired, generalized HSDD in premenopausal women. Yet the compound itself had been studied under the name PT-141 for over a decade before that approval. The difference isn't the molecule. It's the regulatory pathway, the manufacturer, and the price. Vyleesi is FDA-approved, pre-filled, and costs $800–$900 per injection without insurance. PT-141 is compounded by 503B facilities, reconstituted by the user, and typically runs $80–$150 per dose. Same active ingredient. Entirely different market positioning.
- Our team has reviewed this across hundreds of clients in the peptide research space. The confusion between PT-141 vs Vyleesi isn't about efficacy. It's about access, cost, and regulatory classification. Most people don't realize they're choosing between an FDA-approved autoinjector and a compounded version of the identical peptide.
- What's the difference between PT-141 and Vyleesi?
- PT-141 and Vyleesi both contain bremelanotide, a melanocortin receptor agonist that activates MC4R pathways in the hypothalamus to increase sexual desire independent of vascular or hormonal mechanisms. Vyleesi is the FDA-approved, brand-name product sold as a 1.75mg autoinjector pen. PT-141 is the research peptide name for bremelanotide, compounded by FDA-registered 503B pharmacies as a lyophilized powder for subcutaneous injection. The molecule, dose, and mechanism are identical. The regulatory classification and delivery format differ.
- Here's what most comparison guides won't tell you: the PT-141 vs Vyleesi question isn't a choice between two different drugs. It's a choice between paying for FDA approval, manufacturing oversight, and a pre-filled pen. Or sourcing the same peptide through a compounding pharmacy at 80–90% lower cost with the trade-off of self-reconstitution and no FDA batch-level review. Neither option is fake, inferior, or dangerous by default. But the regulatory, cost, and access implications are night-and-day different. This article covers the mechanism both share, the clinical evidence supporting bremelanotide's efficacy, what differentiates FDA-approved Vyleesi from compounded PT-141, and what that distinction means for real-world access, cost, and patient outcomes.